Alexandre Borges

Prof. Dr. Alexandre Borges


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MPMariana Cintra Pagotti
Mariana Cintra Pagotti
Herbert Júnior DiasHerbert Júnior Dias
Herbert Júnior Dias
ACAna Carolina B. B. Candido
Ana Carolina B. B. Candido
TOThaís A. S. Oliveira
Thaís A. S. Oliveira
ABAlexandre Borges
Alexandre Borges
Lizandra MagalhãesLizandra Magalhães
Lizandra Magalhães
Chagas disease is a neglected tropical disease that affects more than 8 million people. Although there are therapies against this disease, the search for new drugs is important because the current treatments show limited effectiveness and high toxicity. In this work, eighteen dihydrobenzofuran-type neolignans (DBNs) and two benzofuran-type neolignans (BNs) were synthesized and evaluated against amastigote forms of two Trypanosoma cruzi strains. The in vitro cytotoxicity and hemolytic activity of the most active compounds were also evaluated and their relationships with T. cruzi tubulin DBNs were investigated by an in silico approach. Four DBNs demonstrated activity against the T. cruzi Tulahuen lac-Z strain (IC50 from 7.96 to 21.12 µM), and DBN 1 exhibited the highest activity against the amastigote forms of the T. cruzi Y strain (IC50 3.26 μM). Compounds 1–4 showed CC50 values higher than antitrypanosomal activities, except for DBN 3. All DBNs with antitrypanosomal activity demonstrated CH50 higher than 100 µM. The in silico results indicated that DBNs 1, 2, and 4 are capable of destabilizing the dynamics of the tubulin-microtubule from the vinca site. These compounds displayed promising in vitro activity against T. cruzi, especially compound 1, and can be considered molecular prototypes for the development of new antiparasitic drugs.

25 July 2023 in Food Bioscience
Verified
Journal Article
Closed access
CLCaroline Honaiser Lescano
Caroline Honaiser Lescano
FLFernando Freitas de Lima
Fernando Freitas de Lima
TCTaline Baganha Stefanello Catelan
Taline Baganha Stefanello Catelan
VGVictor Hugo Dantas Guimarães
Victor Hugo Dantas Guimarães
UPUlisses Pereira
Ulisses Pereira
IOIvan Oliveira
Ivan Oliveira

17 August 2026 in UNIFUNEC CIÊNCIAS DA SAÚDE E BIOLÓGICAS
Verified
Journal Article
Open access
PDF file
EBEduarda Rosa Bigoto
Eduarda Rosa Bigoto
GSGuilherme Henrique Pelarin dos Reis Salviano
Guilherme Henrique Pelarin dos Reis Salviano
IAIsabella Araujo Assis
Isabella Araujo Assis
JFJosé Guilherme Garcia Francisconi
José Guilherme Garcia Francisconi
LSLudmila Pereira da Silva
Ludmila Pereira da Silva
ABAlexandre Borges
Alexandre Borges
O presente estudo consistiu em uma revisão integrativa da literatura sobre a Curcuma longa L., com o objetivo de analisar suas ações farmacológicas, mecanismos de ação e aplicabilidades terapêuticas. A busca foi realizada nas bases de dados PubMed, Scopus e SciELO, abrangendo publicações entre 2014 e 2025. Os resultados indicam que a planta, rica em curcuminoides, apresenta propriedades anti-inflamatórias, antioxidantes, antimicrobianas e neuroprotetoras consistentes. Observou-se que a curcumina atua na modulação de citocinas pró-inflamatórias e fatores de transcrição e enzimas como Fator Nuclear Kappa B (NF-κВ) e Ciclo-oxigenase-2 (СОХ-2). No campo oncológico, o composto demonstra potencial adjuvante ao interferir em vias de apoptose e angiogênese. Contudo, a baixa biodisponibilidade da curcumina, a heterogeneidade metodológica e a ausência de padronização de doses configuram-se como as principais limitações para sua consolidação na prática clínica. Conclui-se que, embora promissora, a utilização da cúrcuma demanda ensaios clínicos mais robustos para o estabelecimento de protocolos terapêuticos definitivos. USE OF CURCUMA LONGA L. AS AN HERBAL MEDICINE IN CLINICAL PRACTICE: AN INTEGRATIVE REVIEW ABSTRACT This study comprised an integrative review of the literature on Curcuma longa L. aimed at analyzing its pharmacological action, mechanisms of action and therapeutic applicability. Publications made between 2014 and 2025 in PubMed, Scopus and SciELO’s databases were surveyed. Results indicate that the plant, which is rich in curcuminoids, offers consistent anti-inflammatory, antioxidant, and antimicrobial properties, in addition to neuroprotective effects. It was observed that curcumin modulates pro-inflammatory cytokines and transcription factors and enzymes such as Nuclear Factor Kappa B (NF-κВ) and Cyclo-oxygenase-2 (СОХ-2). In the field of oncology, the compound has demonstrated an adjuvant potential by interfering with apoptosis and angiogenesis pathways. However, the low bioavailability of curcumin, methodological heterogeneity and a lack of standardization of doses are the main limitations in consolidating the use of curcumin in clinical practice. It was concluded that, although promising, the use of turmeric requires more robust clinical trials to establish definitive therapeutic protocols. Descriptors: Turmeric. Curcumin. herbal medicine. anti-inflammatory. general medicine.